GLP-1 Pricing Guide 2026: Ozempic vs Wegovy vs Mounjaro vs Zepbound Costs

What Are GLP-1 Drugs and Why Do They Cost So Much?

GLP-1 (glucagon-like peptide-1) receptor agonists were originally developed to treat type 2 diabetes by stimulating insulin production and lowering blood sugar. When clinical trials revealed dramatic weight loss as a side effect — 15-22% of body weight in many patients — demand exploded. By 2025, an estimated 30 million Americans had prescriptions for a GLP-1 agonist, making this the fastest-growing drug class in pharmaceutical history.

The cost is driven by three factors: these are injectable biologics that are expensive to manufacture, only two companies (Novo Nordisk and Eli Lilly) control the market, and demand far outstrips supply. With no generic competition expected until 2031-2032, brand manufacturers have significant pricing power.

GLP-1 Drug Price Comparison Table

The table below shows the average Medicare Part D cost per claim (approximately a 30-day supply) for each GLP-1 drug, along with the estimated retail price without insurance.

Source: CMS Medicare Part D Drug Spending Dashboard. Cost per claim reflects the average total cost (plan + patient share) for approximately a 30-day supply.

Without Insurance: $900-1,350 Per Month

Patients paying out of pocket face staggering monthly costs. The brand-name retail prices for GLP-1 drugs range from $900 to $1,350 per month without insurance coverage. Wegovy carries the highest list price at approximately $1,349/month because it is prescribed specifically for weight management, a category many insurers still decline to cover. Mounjaro and Zepbound list at $1,059/month, while Ozempic and Rybelsus (the oral semaglutide option) each cost around $935/month at retail.

With commercial insurance, copays typically range from $25 to $150/month depending on formulary tier and plan design. However, many employer plans and individual market plans exclude weight-loss indications, meaning patients prescribed Wegovy or Zepbound for obesity may face the full retail price even with insurance.

Medicare Negotiated Prices for 2027: 71% Discount

The Inflation Reduction Act gave Medicare the power to negotiate drug prices for the first time. In the second round of negotiations, all semaglutide products — Ozempic, Wegovy, and Rybelsus — were selected for Medicare negotiated pricing effective January 2027.

The negotiated price for semaglutide is approximately $274 per month — a 71% discount from the current average Medicare cost of $685.00-$820.00 per claim. This is projected to save Medicare $8-12 billion annually and will directly benefit the estimated 3.5 million Medicare beneficiaries currently taking semaglutide.

Tirzepatide (Mounjaro/Zepbound) is expected to be included in the third round of Medicare negotiations, with negotiated prices taking effect in 2028 or 2029.

Compounded Semaglutide: $149-299/Month

Compounding pharmacies have emerged as a lower-cost alternative, producing custom-formulated semaglutide injections at $149 to $299 per month — roughly 70-85% less than brand-name prices. Under FDA regulations, compounding pharmacies can produce copies of drugs that are on the FDA's drug shortage list.

However, the legal landscape is shifting. As Novo Nordisk has resolved supply shortages for Ozempic and Wegovy, the FDA has moved to remove semaglutide from the shortage list, which would end the legal basis for compounding. Several compounding pharmacies have filed legal challenges, and court rulings are expected throughout 2026. Patients currently using compounded semaglutide should monitor these developments closely.

TrumpRx Pricing: Ozempic at $199-350

The TrumpRx executive order program, announced in early 2026, negotiated direct pricing agreements with pharmaceutical manufacturers to offer select drugs at reduced prices through participating pharmacies. Under this program, Ozempic is available at $199 to $350 per month depending on dosage, representing a 63-79% discount from retail.

Eligibility for TrumpRx pricing requires enrollment through the program's portal and filling prescriptions at participating pharmacies. The program is available to all patients regardless of insurance status, though it cannot be combined with Medicare or Medicaid benefits. As of April 2026, Wegovy and Mounjaro/Zepbound are not yet included in the program but are expected to be added later in the year.

How to Save on GLP-1 Medications

With so many pricing options available, patients have more ways than ever to reduce their GLP-1 costs:

• Manufacturer savings cards — Novo Nordisk and Eli Lilly both offer copay savings programs that can reduce commercially insured costs to as low as $25/month. Check each drug maker's website for current offers.
• Patient assistance programs (PAPs) — For uninsured or underinsured patients, both manufacturers offer free or reduced-cost medication. Income thresholds vary but typically cover households up to 400% of the federal poverty level.
• Medicare negotiated prices — Starting January 2027, Medicare beneficiaries will pay approximately $274/month for semaglutide products. See our Medicare negotiated prices page for the full list of drugs with negotiated rates.
• Compounded versions — While legally available, compounded semaglutide at $149-299/month offers the lowest price point. Verify your pharmacy is licensed and uses FDA-registered ingredients.
• TrumpRx program — Ozempic at $199-350/month through participating pharmacies, no insurance required.
• Oral semaglutide (Rybelsus) — For diabetes patients, the oral tablet form may have different formulary placement and lower copays than the injectable versions.
• Trulicity as a lower-cost alternative — At $473.00 per claim, Trulicity (dulaglutide) costs significantly less than Ozempic or Mounjaro, though weight loss effects are more modest.

Generic Timeline: No Relief Before 2031

Patients hoping for generic GLP-1 drugs will need to wait. Novo Nordisk holds multiple patents on semaglutide extending through 2031, and Eli Lilly's tirzepatide patents run through 2032. Even after patent expiration, biosimilar development for injectable biologics typically takes 3-5 years, meaning affordable generic alternatives may not reach pharmacies until 2034-2037.

The one near-term exception is dulaglutide (Trulicity), whose core patents begin expiring in 2027. Several biosimilar manufacturers have announced development programs, and the first generic dulaglutide could reach the market by 2028-2029. Check our GLP-1 agonist class page for the latest patent and generic timeline updates.

The Bottom Line

GLP-1 drugs remain among the most expensive medications in America, with brand prices ranging from $473.00 to $673.00 per Medicare claim and $900-1,350/month at retail without insurance. The most significant price relief is coming through Medicare negotiation ($274/month for semaglutide in 2027), compounded alternatives ($149-299/month), and the TrumpRx program ($199-350 for Ozempic). No generic semaglutide or tirzepatide is expected before 2031-2032.